Skip to content

Study · Animal study (in vivo) · mouse · 2005

7 results

Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice.

Heijboer AC, van den Hoek AM, Pijl H, Voshol PJ, Havekes LM, Romijn JA, Corssmit EP

Diabetologia22 Jun 2005Cited by 34 (Europe PMC)

PMID15971058 (opens in a new tab)DOI10.1007/s00125-005-1838-8 (opens in a new tab)PepBankPUB-15971058
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male C57Bl/6 mice, intracerebroventricular melanotan II did not change plasma glucose under basal or hyperinsulinaemic conditions compared with control.

    In plain wordsIn mice, melanotan II given into the brain did not change blood sugar levels compared with controls.

    Peptide
    Melanotan II
    Outcome
    No significant changePlasma glucose concentration, basal and hyperinsulinaemic
    Study

    mousen: not reported in source

    Male C57Bl/6 mice, hyperinsulinaemic-euglycaemic clamp
    Comparator
    Vehicle (distilled water)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    225 ng in three aliquots · intracerebroventricular · 24 hoursAs given in this study (mouse).

    Source sentences

    Summary
    Plasma glucose and insulin concentrations under basal and hyperinsulinaemic conditions were similar in MTII- and placebo-treated mice.
    1 context sentence
    Summary · context
    Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the left lateral ventricle of male C57Bl/6 mice. The animals had no access to food. The control group received three injections of distilled water.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male C57Bl/6 mice, intracerebroventricular melanotan II did not change plasma insulin under basal or hyperinsulinaemic conditions compared with control.

    In plain wordsIn mice, melanotan II given into the brain did not change insulin levels compared with controls.

    Peptide
    Melanotan II
    Outcome
    No significant changePlasma insulin concentration, basal and hyperinsulinaemic
    Study

    mousen: not reported in source

    Male C57Bl/6 mice, hyperinsulinaemic-euglycaemic clamp
    Comparator
    Vehicle (distilled water)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    225 ng in three aliquots · intracerebroventricular · 24 hoursAs given in this study (mouse).

    Source sentences

    Summary
    Plasma glucose and insulin concentrations under basal and hyperinsulinaemic conditions were similar in MTII- and placebo-treated mice.
    1 context sentence
    Summary · context
    Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the left lateral ventricle of male C57Bl/6 mice. The animals had no access to food. The control group received three injections of distilled water.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male C57Bl/6 mice, intracerebroventricular melanotan II significantly increased basal endogenous glucose production compared with control.

    In plain wordsIn mice, melanotan II given into the brain raised the liver's own glucose output at rest compared with controls.

    Peptide
    Melanotan II
    Outcome
    IncreaseBasal endogenous glucose production
    Study

    mousen: not reported in source

    Male C57Bl/6 mice, hyperinsulinaemic-euglycaemic clamp
    Comparator
    Vehicle (distilled water)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    225 ng in three aliquots · intracerebroventricular · 24 hoursAs given in this study (mouse).

    Measurements

    Endogenous glucose production
    71 micromol.min(-1).kg(-1)
    MTII
    Endogenous glucose production
    43 micromol.min(-1).kg(-1)
    control

    Source sentences

    Summary
    Endogenous glucose production (EGP) and glucose disposal in the basal state were significantly higher in MTII-treated mice than in the control group (71+/-22 vs 43+/-12 micromol.min(-1).kg(-1), p<0.01).
    1 context sentence
    Summary · context
    Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the left lateral ventricle of male C57Bl/6 mice. The animals had no access to food. The control group received three injections of distilled water.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In male C57Bl/6 mice, intracerebroventricular melanotan II significantly increased basal glucose disposal compared with control.

    In plain wordsIn mice, melanotan II given into the brain increased glucose disposal at rest compared with controls.

    Peptide
    Melanotan II
    Outcome
    IncreaseBasal glucose disposal
    Study

    mousen: not reported in source

    Male C57Bl/6 mice, hyperinsulinaemic-euglycaemic clamp
    Comparator
    Vehicle (distilled water)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    225 ng in three aliquots · intracerebroventricular · 24 hoursAs given in this study (mouse).

    Source sentences

    Summary
    Endogenous glucose production (EGP) and glucose disposal in the basal state were significantly higher in MTII-treated mice than in the control group (71+/-22 vs 43+/-12 micromol.min(-1).kg(-1), p<0.01).
    1 context sentence
    Summary · context
    Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the left lateral ventricle of male C57Bl/6 mice. The animals had no access to food. The control group received three injections of distilled water.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In male C57Bl/6 mice, intracerebroventricular melanotan II significantly increased glucose disposal during hyperinsulinaemia compared with control.

    In plain wordsIn mice, melanotan II given into the brain increased insulin-driven glucose disposal compared with controls.

    Peptide
    Melanotan II
    Outcome
    IncreaseGlucose disposal during hyperinsulinaemia
    Study

    mousen: not reported in source

    Male C57Bl/6 mice, hyperinsulinaemic-euglycaemic clamp
    Comparator
    Vehicle (distilled water)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    225 ng in three aliquots · intracerebroventricular · 24 hoursAs given in this study (mouse).

    Measurements

    Glucose disposal
    151 micromol.min(-1).kg(-1)
    MTII, hyperinsulinaemia
    Glucose disposal
    108 micromol.min(-1).kg(-1)
    control, hyperinsulinaemia

    Source sentences

    Summary
    During hyperinsulinaemia, glucose disposal was significantly higher in MTII-treated mice (151+/-20 vs 108+/-20 micromol.min(-1).kg(-1), p<0.01).
    1 context sentence
    Summary · context
    Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the left lateral ventricle of male C57Bl/6 mice. The animals had no access to food. The control group received three injections of distilled water.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In male C57Bl/6 mice, melanotan II did not affect the inhibitory effect of insulin on endogenous glucose production.

    In plain wordsIn mice, melanotan II did not change how well insulin switched off the liver's glucose output compared with controls.

    Peptide
    Melanotan II
    Outcome
    No significant changeInsulin suppression of endogenous glucose production
    Study

    mousen: not reported in source

    Male C57Bl/6 mice, hyperinsulinaemic-euglycaemic clamp
    Comparator
    Vehicle (distilled water)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    225 ng in three aliquots · intracerebroventricular · 24 hoursAs given in this study (mouse).

    Measurements

    Relative decrease in EGP
    45%
    MTII
    Relative decrease in EGP
    50%
    control

    Source sentences

    Summary
    In contrast, the inhibitory effect of insulin on EGP was not affected by MTII (relative decrease in EGP: 45+/-27 vs 50+/-20%).
    1 context sentence
    Summary · context
    Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the left lateral ventricle of male C57Bl/6 mice. The animals had no access to food. The control group received three injections of distilled water.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In male C57Bl/6 mice, intracerebroventricular melanotan II significantly increased Glut4 mRNA expression in skeletal muscle compared with control.

    In plain wordsIn mice, melanotan II given into the brain raised Glut4 gene activity in muscle compared with controls.

    Peptide
    Melanotan II
    Outcome
    IncreaseGlut4 mRNA expression in skeletal muscle
    Study

    mousen: not reported in source

    Male C57Bl/6 mice, hyperinsulinaemic-euglycaemic clamp
    Comparator
    Vehicle (distilled water)
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    225 ng in three aliquots · intracerebroventricular · 24 hoursAs given in this study (mouse).

    Measurements

    Glut4 mRNA expression
    307%
    MTII
    Glut4 mRNA expression
    100%
    control

    Source sentences

    Summary
    Glut4 mRNA expression in skeletal muscle was significantly increased in MTII-treated mice (307+/-94 vs 100+/-56%, p<0.01).
    1 context sentence
    Summary · context
    Over a period of 24 h, 225 ng of MTII was injected in three aliquots into the left lateral ventricle of male C57Bl/6 mice. The animals had no access to food. The control group received three injections of distilled water.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.